(NASDAQ: OABI) Omniab's forecast annual revenue growth rate of 41.48% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 115.73%, and while it is forecast to beat the US market's average forecast revenue growth rate of 23.06%.
Omniab's revenue in 2026 is $21,094,000.On average, 8 Wall Street analysts forecast OABI's revenue for 2026 to be $4,698,128,434, with the lowest OABI revenue forecast at $3,258,862,345, and the highest OABI revenue forecast at $6,801,892,650. On average, 8 Wall Street analysts forecast OABI's revenue for 2027 to be $6,602,946,287, with the lowest OABI revenue forecast at $4,077,104,839, and the highest OABI revenue forecast at $11,610,578,832.
In 2028, OABI is forecast to generate $8,619,473,530 in revenue, with the lowest revenue forecast at $5,445,544,871 and the highest revenue forecast at $12,999,172,620.